The post Solana Price Set for Q4 Surge as Canary Capital ETF Filing appeared on BitcoinEthereumNews.com. The Solana price narrative continues to gain traction as market voices highlight both technical accumulation and institutional interest. Pseudonymous analyst Zyn has tied the Wyckoff phases to Solana’s ongoing structure, sparking curiosity about its next moves. Meanwhile, Canary Capital’s ETF filing adds another layer of attention, positioning Solana among digital assets increasingly considered for regulated products.  Solana Price Action Across Wyckoff Phases Specifically, the analyst outlines Solana’s structured move through the Wyckoff accumulation phases with precise timelines and levels. Phase A began in March 2024, where the SOL price ranged around $204 before dropping to $125 by July.  Notably, phase B extended from July 2024, rallying to $293 before correcting sharply to $95 by April 2025. Phase C followed in April 2025, climbing from $95 to $187 in May before pulling back again to test support near $126 in June.  Phase D then picked up strength, pushing SOL price to $254 in September 2025 before retracing to the current Solana market price, which trades at  around $194.  Phase E is expected to unfold next, with the expert projecting a potential 157% rally from current levels. The long-term Solana price forecast highlights the possibility of the asset climbing as high as $500, completing the Wyckoff cycle. SOL/USDT 1-Week (Source: X) Canary Capital Accelerates ETF Filing Momentum Notably, Canary Capital has filed for a Solana ETF, marking one of the first formal pushes to bring SOL into the regulated investment sphere. This filing specifically highlights staking and holding mechanisms, which distinguish the product from traditional spot offerings.  The move has been perceived as both a strategic step and a potential confidence booster for the Solana ecosystem. Meanwhile, institutional visibility often fuels stronger adoption patterns, even before approvals come through.  At the same time, Grayscale recently  launched its CoinDesk Crypto 5 ETF, which… The post Solana Price Set for Q4 Surge as Canary Capital ETF Filing appeared on BitcoinEthereumNews.com. The Solana price narrative continues to gain traction as market voices highlight both technical accumulation and institutional interest. Pseudonymous analyst Zyn has tied the Wyckoff phases to Solana’s ongoing structure, sparking curiosity about its next moves. Meanwhile, Canary Capital’s ETF filing adds another layer of attention, positioning Solana among digital assets increasingly considered for regulated products.  Solana Price Action Across Wyckoff Phases Specifically, the analyst outlines Solana’s structured move through the Wyckoff accumulation phases with precise timelines and levels. Phase A began in March 2024, where the SOL price ranged around $204 before dropping to $125 by July.  Notably, phase B extended from July 2024, rallying to $293 before correcting sharply to $95 by April 2025. Phase C followed in April 2025, climbing from $95 to $187 in May before pulling back again to test support near $126 in June.  Phase D then picked up strength, pushing SOL price to $254 in September 2025 before retracing to the current Solana market price, which trades at  around $194.  Phase E is expected to unfold next, with the expert projecting a potential 157% rally from current levels. The long-term Solana price forecast highlights the possibility of the asset climbing as high as $500, completing the Wyckoff cycle. SOL/USDT 1-Week (Source: X) Canary Capital Accelerates ETF Filing Momentum Notably, Canary Capital has filed for a Solana ETF, marking one of the first formal pushes to bring SOL into the regulated investment sphere. This filing specifically highlights staking and holding mechanisms, which distinguish the product from traditional spot offerings.  The move has been perceived as both a strategic step and a potential confidence booster for the Solana ecosystem. Meanwhile, institutional visibility often fuels stronger adoption patterns, even before approvals come through.  At the same time, Grayscale recently  launched its CoinDesk Crypto 5 ETF, which…

Solana Price Set for Q4 Surge as Canary Capital ETF Filing

2025/09/27 00:30

The Solana price narrative continues to gain traction as market voices highlight both technical accumulation and institutional interest. Pseudonymous analyst Zyn has tied the Wyckoff phases to Solana’s ongoing structure, sparking curiosity about its next moves. Meanwhile, Canary Capital’s ETF filing adds another layer of attention, positioning Solana among digital assets increasingly considered for regulated products. 

Solana Price Action Across Wyckoff Phases

Specifically, the analyst outlines Solana’s structured move through the Wyckoff accumulation phases with precise timelines and levels. Phase A began in March 2024, where the SOL price ranged around $204 before dropping to $125 by July. 

Notably, phase B extended from July 2024, rallying to $293 before correcting sharply to $95 by April 2025. Phase C followed in April 2025, climbing from $95 to $187 in May before pulling back again to test support near $126 in June. 

Phase D then picked up strength, pushing SOL price to $254 in September 2025 before retracing to the current Solana market price, which trades at  around $194. 

Phase E is expected to unfold next, with the expert projecting a potential 157% rally from current levels. The long-term Solana price forecast highlights the possibility of the asset climbing as high as $500, completing the Wyckoff cycle.

SOL/USDT 1-Week (Source: X)

Canary Capital Accelerates ETF Filing Momentum

Notably, Canary Capital has filed for a Solana ETF, marking one of the first formal pushes to bring SOL into the regulated investment sphere. This filing specifically highlights staking and holding mechanisms, which distinguish the product from traditional spot offerings. 

The move has been perceived as both a strategic step and a potential confidence booster for the Solana ecosystem. Meanwhile, institutional visibility often fuels stronger adoption patterns, even before approvals come through. 

At the same time, Grayscale recently  launched its CoinDesk Crypto 5 ETF, which includes Solana alongside Bitcoin, Ethereum, XRP, and Cardano. This transition from the former GDLC fund to a regulated ETF expands exposure for major institutions. It also positions Solana next to some of the most widely recognized assets in global finance.

Together, these ETF initiatives provide significant credibility for Solana and strengthen the case for mainstream adoption. Institutional recognition not only adds visibility but could also enhance long-term investor confidence.

Summary

The Solana price remains anchored by technical resilience and institutional catalysts. Phase-based analysis continues to validate its structured path toward higher levels. Meanwhile, the ETF filing strengthens the broader narrative, giving the SOL price greater long-term visibility. Ultimately, the $500 target highlighted by the analyst stands as a powerful reminder of Solana’s upside potential.

Source: https://coingape.com/markets/solana-price-set-for-q4-surge-as-canary-capital-etf-filing-meets-wyckoff-accumulation/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Share Insights

You May Also Like

New Viral Presale on XRPL: DeXRP Surpassed $6.4 Million

New Viral Presale on XRPL: DeXRP Surpassed $6.4 Million

The post New Viral Presale on XRPL: DeXRP Surpassed $6.4 Million  appeared on BitcoinEthereumNews.com. One of the most talked-about ecosystems in the cryptocurrency space is the XRP Ledger (XRPL), and DeXRP, the first Presale on XRPL, recently made headlines for its growth story. Attracting over 9,300 investors globally, the project has now raised over $6.4 million and is rapidly emerging as one of the most viral cryptocurrency launches of 2025. By integrating AMM and Order Book trading with a cutting-edge LP system and an open voting process for holders, DeXRP hopes to establish itself as the preferred trading destination for the XRPL community. What is DeXRP?  As the first decentralized exchange (DEX) based on XRPL, DeXRP is taking center stage as XRP continues to solidify its place in the global market. Massive expectation has been generated by the combination of DeXRP’s ambition for an advanced trading platform and XRPL’s established infrastructure, which is renowned for its quick transactions, cheap fees, and institutional-ready capabilities. In contrast to a lot of speculative presales, DeXRP’s development shows both institutional interest and community-driven momentum. Its early achievement of the $6.4 million milestone demonstrates how rapidly investors are realizing its potential. DeXRP Presale Success More than 9,300 distinct wallets have already joined the DeXRP presale, indicating a high level of interest from around the world. A crucial aspect is highlighted by the volume and variety of participation: DeXRP is not merely a niche project; rather, it is emerging as a major force in the XRPL ecosystem. DeXRP’s recent collaborations with WOW Earn and Micro3, as well as its sponsorship of the WOW Summit in Hong Kong, are also contributing factors to this uptick in investor confidence. These actions are blatant attempts to increase the company’s awareness among institutional players and crypto-native groups. The Forbes article summed it up: DeXRP is embedding credibility where others chase hype, marking it as…
Share
2025/09/18 20:14
Share
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
2025/09/18 05:26
Share